GeoVax Labs Inc
Filed Sep 6, 2024.
View on SEC.govAbout this filing
A company's registration of shares for sale to the public, often for a first offering. It describes the business, its risks and how the company plans to use the money.
period unavailable · Filed Sep 6, 2024
Contents
Preclinical Development Programs
| Product | Indication | Status |
|---|---|---|
| GEO-MVA-MUC1 | Solid Tumor Cancers | Humanized Mouse Model (completed) |
| GEO-CM02 | Pan-Coronavirus Vaccine | Humanized Mouse Model (completed) |
| GEO-EM01-Z | Ebola Zaire Vaccine** | Non-Human Primate (completed) |
| GEO-EM01-S | Ebola Sudan Vaccine** | Non-Human Primate (completed) |
| GEO-MM01 | Marburg Vaccine** | Non-Human Primate (completed) |
| GEO-ZM02 | Zika Vaccine** | Mouse Model (completed) |
| GEO-MVA | Mpox & Smallpox Vaccine | Regulatory Discussions & Manufacturing Scale-up |
** Orphan Drug status granted*
*** Indication within FDA Priority Review Voucher program*
Our programs are in various stages of development, the most significant of which are summarized below along with recent developments. We have not generated any revenues from the sale of the products we are developing, and we do not expect to generate any such revenues for at least the next several years. Our product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that we advance to clinical testing will require regulatory approval prior to commercial use and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.